These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8211557)

  • 1. [Combined therapy with mitoxantrone and cytosine arabinoside as a first-line treatment in ANLL: preliminary results].
    Angós JA; Gutiérrez M; Moreno JA; Aguado MJ; Romero MS
    Sangre (Barc); 1993 Jun; 38(3):250-1. PubMed ID: 8211557
    [No Abstract]   [Full Text] [Related]  

  • 2. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
    Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
    Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
    van der Jagt RH
    Leuk Res; 2010 Jul; 34(7):856-7. PubMed ID: 20378170
    [No Abstract]   [Full Text] [Related]  

  • 4. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 5. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Savani B
    Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The first Russian trial of treating patients with acute nonlymphoblastic leukemias with novantrone combined with cytosar].
    Volkova MA; Kaletin GI
    Ter Arkh; 1992; 64(7):18-21. PubMed ID: 1440359
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872.
    Béhar C; Suciu S; Benoit Y; Robert A; Vilmer E; Boutard P; Bertrand Y; Lutz P; Ferster A; Tokaji E; Manel AM; Solbu G; Otten J
    Med Pediatr Oncol; 1996 Mar; 26(3):173-9. PubMed ID: 8544799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia.
    Nachbaur K; Dietze O; Herold M; Thaler J; Braunsteiner H; Vogel W
    Eur J Haematol; 1992 Oct; 49(4):221-3. PubMed ID: 1464366
    [No Abstract]   [Full Text] [Related]  

  • 10. Mitoxantrone in the treatment of refractory and relapsed non-lymphoblastic acute leukaemia.
    Pretnar J
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():59-60. PubMed ID: 2697403
    [No Abstract]   [Full Text] [Related]  

  • 11. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
    Salvucci M; Zanchini R; Molinari A; Zuffa E; Poletti V; Poletti G; Zaccaria A
    Haematologica; 2000 Jul; 85(7):769-70. PubMed ID: 10897135
    [No Abstract]   [Full Text] [Related]  

  • 13. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
    Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
    Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
    Hiddemann W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Becker K; Balleisen L; Lathan B
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):35-8. PubMed ID: 1780750
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.
    Jakl M; Horacek JM; Jebavy L; Pudil R
    Leuk Res; 2009 Aug; 33(8):e109-10. PubMed ID: 19237194
    [No Abstract]   [Full Text] [Related]  

  • 16. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
    Lemez P; Urbánek V
    Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
    Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of poor prognosis acute myeloid leukemia with aggressive and non-aggressive chemotherapy.
    Stenke L; Hast R; Reizenstein P
    Chemioterapia; 1987 Jun; 6(2 Suppl):723-4. PubMed ID: 3509530
    [No Abstract]   [Full Text] [Related]  

  • 20. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
    Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.